GSK Sarcoma Drug Prevails at Advisory Panel While Merck Treatment Falls Flat

An FDA advisory panel voted 11–2 in favor of GlaxoSmithKline’s cancer drug Votrient Tuesday, moving the drug one step closer to a supplemental indication for soft tissue sarcoma patients who have received prior chemotherapy. Oncologic Drugs Advisory Committee members acknowledged it demonstrated only marginal benefit — halting disease progression by three months — but concluded that even a small advantage is meaningful given the high unmet medical need for the rare disease population.
Drug Industry Daily